Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- ‘Tremendous implications’: Hospital affiliation linked to higher-cost care (Healio)
- Omada Health Launches AI-Powered Meal Map to Transform Nutrition for Cardiometabolic Patients (HIT Consultant)
- 10 Must-Read Posts in GI Oncology This Week (OncoDaily)
- SCA Health expands GI footprint, physician network in 2025 (Becker’s GI & Endoscopy)
- 7 key numbers on the state of GI in 2025 (Becker’s GI & Endoscopy)
- White House Unveils ‘TrumpRx’ Drug-Buying Site and a Pfizer Pricing Deal (The Wall Street Journal)
- CADe for Colonoscopy: Positive and Negative Takeaways From Largest Real-World Study (GI & Endoscopy News)
- FDA OKs Tremfya for Ulcerative Colitis (GI & Hepatology News)